Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube Mar 11, 2026
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube Mar 11, 2026
Company Drug

Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment

Fineline Cube Jul 20, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...

Company Legal / IP

Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case

Fineline Cube Jul 20, 2023

Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against...

Company Deals

Boyu Capital Acquires Hong Kong Medical Device Company Quasar for Over $600 Million

Fineline Cube Jul 19, 2023

Boyu Capital, according to a Bloomberg report, is set to acquire Quasar, a Hong Kong-based...

Company

Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth

Fineline Cube Jul 19, 2023

Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second...

Company Deals

Shanghai Pharmaceuticals and Mindray Form Strategic Alliance for Medical Equipment and IVD Products

Fineline Cube Jul 19, 2023

Shanghai Pharmaceuticals (SHA: 601607, HKG: 2607), a leading pharmaceutical company in China, has announced a...

Company Deals

MindRank Ltd Secures Over $20 Million in Series A+ Funding to Advance AI Drug Development

Fineline Cube Jul 19, 2023

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd has reportedly secured more than USD 20...

Company Deals

Zhejiang Dian Diagnostics Partners with Northeast Infectious Diseases Alliance to Enhance Surveillance

Fineline Cube Jul 19, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics specialist based in China, has...

Company Deals

Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion

Fineline Cube Jul 19, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a...

Company Deals

Allen Institute for Immunology Partners with Eli Lilly to Study Atopic Dermatitis and Rheumatoid Arthritis

Fineline Cube Jul 19, 2023

The US-based Allen Institute for Immunology has announced a strategic partnership with compatriot company Eli...

Company Deals

Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development

Fineline Cube Jul 19, 2023

Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week...

Company Drug

Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China

Fineline Cube Jul 19, 2023

Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced...

Company Deals

Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project

Fineline Cube Jul 19, 2023

This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...

Company Deals

Sumitomo Pharma to Invest $30 Million in China for New Product Development

Fineline Cube Jul 19, 2023

Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of...

Company Drug

Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab

Fineline Cube Jul 19, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...

Company Drug

Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review

Fineline Cube Jul 19, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...

Company Deals Medical Device

Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics

Fineline Cube Jul 19, 2023

Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD...

Company Drug

Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus

Fineline Cube Jul 18, 2023

France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...

Drug Policy / Regulatory

NMPA Releases 70th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 18, 2023

The National Medical Products Administration (NMPA) has released the 70th batch of reference drugs for...

Company Deals

Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia

Fineline Cube Jul 18, 2023

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China

Fineline Cube Jul 18, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Posts pagination

1 … 468 469 470 … 633

Recent updates

  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
  • Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
  • Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.